References
- Moosdeen F, Keeble J, Williams JD. Induction/inhibition of chromosomal β-lactamases by β-lactamase inhibitors. Rev Infect Dis 1986; 8 (suppl 5): 562–7.
- Stratton CW, Weeks LS, Aldridge K. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group. Diagn Microbiol Infect Dis 1992; 15: 321–30.
- Jones RN, Pfaller MA, Fuchs PC, Aldridge K, Allen SD, Gerlach EH. Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains. Diagn Microbiol Infect Dis 1989; 12: 489–94.
- Fass RJ, Prior RB. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. Antimicrob Agents Chemother 1989; 33: 1268–74.
- Bourgault AM, Lamothe F, Hoban DJ, et al. Survey of Bacteroides fragilis group susceptibility patterns in Canada. Antimicrob Agents Chemother 1992; 36: 343–7.
- Dornbusch K, Mortsell E, Goransson E. In vitro activity of cefepime, a new parenteral cephalosporin, against recent European blood isolates and in comparison with piperacillin/tazobactam. Chemotherapy 1990; 36: 259–67.
- Bauernfeind A, Schweighart S, Eberlein E, Jungwirth R. In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin). Infection 1991; 19 (suppl 5): 264–75.
- Duex JM, Cordin X, Pechinot A, Siebor E, Kazmierczak A. In vitro synergistic activity of piperacillin-tazobactam combination against beta-lactam antibiotics resistant strains of Enterobacteriaceae. Pathol Biol (Paris) 1991; 39: 374–78.
- Soussy CJ, Kitzis MD, Chanal C, Carret G, Derlot E. In vitro antibacterial activity of piperacillin-tazobactam combination on hospital isolates and regression curve. Pathol Biol (Paris) 1991; 39: 367–73.
- Gatermann S, Marre R. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and Proteus mirabilis harboring known beta-lactamases. Infection 1991; 19: 106–9.
- Chang SC, Hsu LY, Luh KT, Hsieh WC. Antimicrobial activities of piperacillin alone and in combination with tazobactam against beta-lactamase-producing bacteria. Taiwan I Hsueh Hui Tsa Chih 1991; 90: 947–52.
- Teng LJ, Ho SW, Chang SC, Luh KT, Hsieh WC. In vitro activities of 36 antimicrobial agents against clinically isolated Bacteroides fragilis. Taiwan I Hsueh Hui Tsa Chih 1991; 90: 796–9.
- National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests, 4th. ed. Approved standard M2-A4. National Committee for Clinical Laboratory Standards. Villanova, PA. 1990.
- Mouton Y, Leroy O, Beuscart C, et al. Efficacy, safety, and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections. J Antimicrob Chemother 1993; 31 (suppl A): 87–95.
- Gould IM, Ansari A, Harvey G, Douglas JC, Smith CC, Reid TM. Piperacillin/tazobactam in the treatment of serious acute soft tissue infection. Drugs Exp Clin Res 1991; 17: 187–90.
- Micozzi A, Nucci M, Vendetti M, et al. Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients. Eur J Clin Microbiol Infect Dis 1993; 12: 1–8.
- Eliopoulos GM, Klimm K, Ferrato MJ, Jacoby GA, Moellering RC Jr. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830). Diagn Microbiol Infect Dis 1989; 12: 481–8.
- Akova M, Yang Y, Livermore DM. Interactions of tazobactam and clavulanate with inducible and constitutively-expressed class I beta-lactamases. J Antimicrob Chemother 1990; 25: 199–208.
- Fass RJ, Prior RB. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. Antimicrob Agents Chemother 1991; 33: 1268–74.
- Thompson KS, Weber DA, Sanders CC, Sanders WE Jr. Beta-lactamase production in members of the family Enter-obacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations. Antimicrob Agents Chemother 1990; 34: 622–7.